Abstract
Background The aggressive biological behavior and the lack of target therapy prompts the search for new therapeutic approaches for triple-negative breast cancers. Patients and Methods We evaluated the efficacy in terms of Ki-67 variation and clinical response but also the toxicity of a neoadjuvant regimen based on metronomic principles including ECF (epidoxorubicin with cisplatin on day 1 with low-dose 5-fluorouracil in continuous infusion every 21 days for 4 courses) followed by paclitaxel (90 mg/m2) on day 1, 8, and 15 every 28 days for 3 courses in combination with metronomic oral cyclophosphamide 50 mg/d for 12 weeks in patients with HER2-negative breast cancer (T2-T4a-d, N0-3, M0) with estrogen receptor and progesterone receptor <10%. Results We enrolled 34 patients from June 2009 to May 2013. All were considered evaluable on an intention-to treat basis. The mean difference between the percentage of Ki-67 positive cells evaluated in surgical resection specimens and in pretreatment tumor core biopsy was 41% (95% confidence interval [CI], 30-51; P
| Original language | English |
|---|---|
| Pages (from-to) | 259-265 |
| Number of pages | 7 |
| Journal | Clinical Breast Cancer |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Keywords
- Chemotherapy
- Ki-67
- Metronomic therapy
- Neoadjuvant
- Pathological complete response
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer. / Cancello, Giuseppe; Bagnardi, Vincenzo; Sangalli, Claudia; Montagna, Emilia; Dellapasqua, Silvia; Sporchia, Andrea; Iorfida, Monica; Viale, Giuseppe; Barberis, Massimo; Veronesi, Paolo; Luini, Alberto; Intra, Mattia; Goldhirsch, Aron; Colleoni, Marco.
In: Clinical Breast Cancer, Vol. 15, No. 4, 2015, p. 259-265.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer
AU - Cancello, Giuseppe
AU - Bagnardi, Vincenzo
AU - Sangalli, Claudia
AU - Montagna, Emilia
AU - Dellapasqua, Silvia
AU - Sporchia, Andrea
AU - Iorfida, Monica
AU - Viale, Giuseppe
AU - Barberis, Massimo
AU - Veronesi, Paolo
AU - Luini, Alberto
AU - Intra, Mattia
AU - Goldhirsch, Aron
AU - Colleoni, Marco
PY - 2015
Y1 - 2015
N2 - Background The aggressive biological behavior and the lack of target therapy prompts the search for new therapeutic approaches for triple-negative breast cancers. Patients and Methods We evaluated the efficacy in terms of Ki-67 variation and clinical response but also the toxicity of a neoadjuvant regimen based on metronomic principles including ECF (epidoxorubicin with cisplatin on day 1 with low-dose 5-fluorouracil in continuous infusion every 21 days for 4 courses) followed by paclitaxel (90 mg/m2) on day 1, 8, and 15 every 28 days for 3 courses in combination with metronomic oral cyclophosphamide 50 mg/d for 12 weeks in patients with HER2-negative breast cancer (T2-T4a-d, N0-3, M0) with estrogen receptor and progesterone receptor <10%. Results We enrolled 34 patients from June 2009 to May 2013. All were considered evaluable on an intention-to treat basis. The mean difference between the percentage of Ki-67 positive cells evaluated in surgical resection specimens and in pretreatment tumor core biopsy was 41% (95% confidence interval [CI], 30-51; P
AB - Background The aggressive biological behavior and the lack of target therapy prompts the search for new therapeutic approaches for triple-negative breast cancers. Patients and Methods We evaluated the efficacy in terms of Ki-67 variation and clinical response but also the toxicity of a neoadjuvant regimen based on metronomic principles including ECF (epidoxorubicin with cisplatin on day 1 with low-dose 5-fluorouracil in continuous infusion every 21 days for 4 courses) followed by paclitaxel (90 mg/m2) on day 1, 8, and 15 every 28 days for 3 courses in combination with metronomic oral cyclophosphamide 50 mg/d for 12 weeks in patients with HER2-negative breast cancer (T2-T4a-d, N0-3, M0) with estrogen receptor and progesterone receptor <10%. Results We enrolled 34 patients from June 2009 to May 2013. All were considered evaluable on an intention-to treat basis. The mean difference between the percentage of Ki-67 positive cells evaluated in surgical resection specimens and in pretreatment tumor core biopsy was 41% (95% confidence interval [CI], 30-51; P
KW - Chemotherapy
KW - Ki-67
KW - Metronomic therapy
KW - Neoadjuvant
KW - Pathological complete response
UR - http://www.scopus.com/inward/record.url?scp=84946488526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946488526&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2015.03.002
DO - 10.1016/j.clbc.2015.03.002
M3 - Article
C2 - 25933934
AN - SCOPUS:84946488526
VL - 15
SP - 259
EP - 265
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 4
ER -